The amyloid precursor protein (APP) contains a Cu binding domain (CuBD) localized between amino acids 135 and 156 (APP ), which can reduce Cu 2+ to Cu 1+ in vitro. The physiological function of this APP domain has not yet being established; nevertheless several studies support the notion that the CuBD of APP is involved in Cu homeostasis. We used APP synthetic peptides to evaluate their protective properties against Cu 2+ neurotoxicity in a bilateral intra-hippocampal injection model. We found that human APP protects against Cu 2+ -induced neurotoxic effects, such as, impairment of spatial memory, neuronal cell loss, and astrogliosis. APP lacking two histidine residues showed protection against Cu 2+ ; however, APP neurotoxicity. In accordance with recent reports, the CuBD of the Caenorhabditis elegans, APL-1, protected against Cu 2+ neurotoxicity in vivo. We also found that Cu 2+ neurotoxicity is associated with an increase in nitrotyrosine immunofluorescence as well as with a decrease in Cu 2+ uptake. The CuBD of APP therefore may play a role in the detoxification of brain Cu.
elegans (7) . The CuBD sequence is similar among the members of APP family, suggesting an overall conservation on its function or activity.
The normal function of APP is unknown; however, several trophic functions have been suggested for soluble APP (8) (9) (10) (11) (12) (13) . In relation to Cu metabolism, it has been suggested that Cu transport from the extracellular to the intracellular compartment may be mediated by APP (3, 4, 14) . Various studies have suggested that APP has a role in Cu homeostasis (4, (15) (16) (17) (18) . APP and APLP2 knockout mice show specific elevations in Cu 2+ levels of cerebral cortex and liver (15) , while APP transgenic mice (Tg2576) have decreased Cu 2+ levels in brain (17) .
In this work, we have studied the effect of the N-terminal CuBD of APP on Cu 2+ neurotoxicity in vivo. We injected CuCl 2 with CuBD synthetic peptides in the rat hippocampus, and the behavioral changes were evaluated by the Morris water maze task. The hippocampal damage was evaluated by examining neuronal cell loss and astrogliosis. We found that both human wildtype APP and a mutant APP lacking of the histidine residues involved in the Cu binding (His147 and His149) were neuroprotective against CuCl 2 toxicity. However, the CuBD APP peptide lacking Cys144 (involved in the reduction of Cu 2+ to Cu
1+
) was not protective against CuCl 2 neurotoxicity. In accordance with previous studies (16) , CuBD of C. elegans APL-1, protected against CuCl 2 toxicity in vivo. Moreover, we found that the differences in protection against Cu 2+ neurotoxicity may be due to an altered response to oxidative stress. Interestingly, differences in Cu 2+ uptake were also observed, with a higher Cu 2+ uptake when CuCl 2 was injected in the presence of the neuroprotective peptides. Our results are consistent with the idea that APP is involved in the modulation of Cu homeostasis in vivo.
MATERIALS AND METHODS

Synthetic peptides
Peptide corresponding to the human wild-type APP 135-156 sequence (CuBD) was obtained from Chiron Corp. (Emeryville, CA). Variant APP peptides containing a Cys→Ser substitution (APP Cys144→Ser ), and a double His→Ala substitution at positions 147 and 149 (APP His147→Ala/His149→Ala ), were obtained from BioSynthesis Inc. (Lewisville, TX). The corresponding CuBD of C. elegans APL-1 (APP 135-156 C. elegans) was obtained from Genemed Biotechnologies, Inc. (San Francisco, CA). Histidine was from Merck (Darmstadt, Germany). Stock solutions (1 mg/ml) were prepared by dissolving the peptides directly in artificial cerebrospinal fluid (aCSF) containing 130 mM NaCl, 2.6 mM KCl, 4.3 mM MgCl 2 , and 1.8 mM CaCl 2 , pH 7.4.
Incubation of peptides before the injection
Synthetic peptides were mixed with CuCl 2 at 5.0 µM final concentration and were incubated overnight at 4°C or incubated overnight at 37°C and injected bilaterally into the dorsal hippocampus (incubation treatment: I); also peptides were mixed and immediately injected (without incubation treatment: WI). In addition, we carried out metallation of the peptides (dialysis treatment) as described by White and co-workers (16) . Briefly, synthetic peptides (150 µl sample, 10 µM) were mixed with CuCl 2 (150 µl sample, 10 µM); the mixtures were incubated overnight at 37°C and then dialyzed using mini-dialysis cups (500 Da cutoff) (Spectrum Laboratories, Inc., Rancho Dominguez, CA) for 24 h against two changes of aCSF (300 ml per change) at 20°C. The final peptide concentration was determined by a micro BCA protein assay (Pierce Biotechnology, Inc., Rockford, IL).
Surgical and injection protocol
Male Sprague-Dawley rats (300 g, 3 months old) were anesthetized with Equitesin (3.5 ml/Kg i.p.) and injected bilaterally into the dorsal hippocampus (-3.5 mm AP, ±2.0 mm ML and -2.7 mm DV, according to Bregma) following the Paxinos and Watson (19) indications, stereotaxically with a 10 µl Hamilton syringe with 27-gauge stainless steel. Animals were injected bilaterally with 3 µl (at rate of 0.5 µl/min) of 5.0 µM CuCl 2 , in the presence or absence of 5.0 µM CuBD APP peptides in different conditions as described above; aCSF was used as vehicle. Four days after intracerebral injection, rats were trained in the Morris water maze for 2 wk and the performance of the different groups was recorded for analysis. After training, the animals were fixed by intracardiac perfusion to carry out the histochemical procedures.
Behavioral test
All animals were trained in a circular water maze (1.6 m diameter and 75 cm deep, painted black) (20) using a two trial per day regimen. The platform (9 cm diameter) always resided in the center of northwest quadrant (hidden platform quadrant). Water (50 cm deep) was maintained at 19-21°C. Data were gathered with a video tracking system for water maze (HVS Imagem, Hampton, UK). Briefly, rats were trained with two trials a day, for 5 consecutive days, followed by 2 days off, and then trained for 5 additional days. Each trial began when rats were allowed to swim. A trial continued until the animal was put onto the platform for 5 s and returned to its cage. Upon completion of all two trials, rats were removed from the maze, dried, and returned to their cage.
Perfusion and fixation
Animals were anesthetized with Equitesin (3.5 ml/kg ip) before perfusion. Rats were perfused through the heart with saline (0.9% NaCl) followed by fixation with 4% paraformaldehyde in 0.1 M phosphate buffer saline (PBS). Brains were removed from their skulls and postfixed in the same fixative for 3 h at room temperature, followed by 20% sucrose in PBS at 4°C overnight. After fixation, brains were coded to ensure unbiased processing and analysis. The brains were then cut into 30 µm coronal sections with a cryostat (Leitz 1900) at -20°C, from Bregma -1.8 mm to Bregma -4.8 mm (19) . Sections from the same brain were divided in groups for analysis of the Nissl staining (0.3% cresyl violet) and the glial fibrillary acidic protein (GFAP) immunohistochemical staining.
Immunohistochemical staining
Free-floating immunohistochemical procedure was performed as described previously (21) . Washing and dilution of immunoreagents was performed with 0.01 M PBS plus 0.2% Triton X-100 (PBS+T) throughout the experiments, and two PBS+T washes were performed between every antibody incubation. Sections were pretreated with 0.5% H 2 O 2 for 30 min to reduce endogenous peroxidase activity followed by incubation with 3% bovine serum albumin (BSA) at room temperature for 1 h to avoid nonspecific binding. GFAP detection was performed using a rabbit anti-GFAP (1:500) polyclonal antibody incubated overnight at 4°C. A horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG secondary antibody (1:600) was used in GFAP detection incubated for 1 h at room temperature. The staining was developed by incubation with 0.06% diaminobenzidine during 15 min followed by addition of H 2 O 2 (0.01% final concentration) and incubation for 4 min. After immunostaining, all sections were mounted on gelatin-coated slides, air-dried, dehydrated by serial rinses in graded ethanol solutions, cleared with xilene, and cover-slipped with Canada balsam (Merck, Darmstadt, Germany).
Immunofluorescence detection of nitrotyrosine
Fixed brain sections mounted in slides were washed with PBS and PBS+T, and followed by glycine (0.15 M) and NaBH 4 (10 mg/ml) incubations to decrease the background of the reaction. Sections were washed again with PBS and PBS+T and then followed by treatment with 3% BSA at room temperature for 1.5 h to avoid nonspecific binding. Nitrotyrosine detection was performed using an anti-nitrotyrosine (1:100) rabbit immunoaffinity purified IgG antibody (Upstate Biotechnology, Lake Placid, NY), incubated overnight at 4°C. After being washed with PBS+T containing 0.5% BSA, sections were incubated for 2 h at room temperature with an antirabbit IgG-FITC second antibody (1:500). The sections were washed with PBS+T in 0.5% BSA, PBS and finally water. The slides were cover-slipped with fluorescent mounting medium (DAKO, Carpinteria, CA).
Nissl staining
Mounted sections were defatted in xylene and hydrated in ethyl alcohol and water series. Nissl staining (cresyl violet) was performed as described previously (21) .
Image analysis
The number of the cells in the injection site was quantified with the program Image Pro-Express (Carlsbad, CA); digital quantification of nitrotyrosine staining area was measured with Image Tool software (San Antonio, TX). The number of reactive astrocytes, intensity of staining in the soma, and size of the astrocyte soma were quantified with SigmaScan Pro software (Chicago, IL). All the analysis was carried out with at least three x40 pictures of the injection site per treatment. 
Measurement
Statistical analysis
All results were expressed as means ± SE. Two-way ANOVA was also conducted for analyzing data of the water maze. P < 0.05 was regarded as statistically significant.
RESULTS
APP 135-156 protects spatial memory against Cu 2+ toxicity
The human CuBD was used to evaluate its ability to prevent the behavioral impairment caused by the intrahippocampal injection of CuCl 2 . Rats injected with CuCl 2 (5 µM) alone showed spatial memory impairments (Fig. 1A) ; however, animals co-injected with 5 µM CuCl 2 and 5 µM of human APP 135-156 previously incubated for 24h at 4°C behaved like control animals (aCSF injected rats) along the two weeks of training. The protective effect of human APP 135-156 against Cu 2+ neurotoxicity was observed also with two other protocols of incubation: 1) without preincubation, APP peptide was mixed with CuCl 2 and immediately injected; and 2) with preincubation and dialysis (see Materials and Methods) (Fig. 1B) . Therefore, APP in the same molar ratio with CuCl 2 protects against Cu 2+ neurotoxicity. Representative swimming paths at day 8 of training for all each experimental condition are shown in Fig. 1C . These results indicate that human APP 135-156 protects spatial memory against Cu 2+ neurotoxicity.
APP 135-156 diminishes neuronal cell loss and astrogliosis induced by CuCl 2 injection
Rats injected with APP 135-156 and CuCl 2 in all the pre-incubation conditions studied, showed partial neuroprotection of hippocampal morphology, evidenced by a thickening of the upper leaf of the dentate gyrus (DG) (Fig. 2C , D, E) in comparison with CuCl 2 injection, which induced an increased thinning of the upper leaf of the DG (Fig. 2B ). In agreement with this, the quantification of the neuronal cell density in the upper leaf of DG shown a major number of cells in the hippocampus injected with APP 135-156 and CuCl 2 than CuCl 2 alone (Fig. 2J ). The analysis of the astrogliosis showed that the co-injection of human APP 135-156 with CuCl 2 induced only a small astrocytic reaction around the injection site ( Fig. 3C , D, E), in comparison with the CuCl 2 injection alone ( Fig. 2B ) in all the pre-incubation conditions. The presence of hypertrophic astrocytes was analyzed with SigmaScan Pro software using x40 magnification pictures of different rats. The density of reactive astrocytes (Fig. 3J ), the intensity of GFAP staining in the soma (Fig. 3K) , and the size of the reactive astrocyte soma (Fig. 3L) were measured. As observed in the Fig. 3J , the injection of CuCl 2 induced an increase in the density of reactive astrocytes in the injection site, mainly in the upper leaf of the dentate gyrus. Also, the analysis of the intensity of GFAP staining in the astrocyte soma revealed an increased intensity in animals injected with CuCl 2 (Fig. 3K) . Finally, the measurement of the size of the astrocyte soma showed that injection of CuCl 2 induced a significative enlargement of the soma (Fig. 3L) . In contrast, the co-injection of APP 135-156 with CuCl 2 showed a significative decrease on the density of reactive astrocytes, intensity of GFAP staining and size of the reactive astrocyte soma (Fig. 3J-L) . These results indicate that the CuBD of human APP can prevent, at least partially, the neuronal cell loss, the astrogliosis and the appearance of hypertrophic astrocytes in the rat hippocampus induced by CuCl 2 .
Cysteine is a key residue involved in the neuroprotective effects of APP 135-156 against Cu
2+ neurotoxicity
It has been previously shown that the N-terminal region of APP is able to bind and reduce Cu 2+ to Cu 1+ (3, 4, 23) . To elucidate which of these APP biochemical properties were responsible for the neuroprotective effects of APP 135-156 , we used synthetic peptides without the Cu binding residues (APP His147→Ala/His149→Ala ) or without the Cu-reducing residue (APP Cys144→Ser ). Rats injected with CuCl 2 plus APP His147→Ala/His149→Ala (incubated overnight at 4°C) showed protection of spatial memory ( Fig. 4A ; see Fig. 4E for representative swimming paths for each treatment at day 8 of training), as also occurs with rats co-injected with CuCl 2 and the wild-type APP 135-156 (see Fig. 1A ). The same neuroprotective effect was observed with APP His147→Ala/His149→Ala when it was pre-incubated with CuCl 2 , dialyzed and then injected (Fig. 4B) . These results strongly suggest that the CuCl 2 binding ability of the N-terminal domain of human APP is not strictly involved in the neuroprotection observed in this model. Nissl staining of hippocampal sections of rats co-injected with CuCl 2 and APP His147→Ala/His149→Ala in conditions of pre-incubation or dialysis did not show important neuronal cell loss in the upper leaf of the DG (Fig. 2G ), indicating that this peptide was able to prevent the neuronal cell loss induced by CuCl 2 (for comparison see Fig.  2B ), which was confirmed in a digital quantification of the neuronal cell density (Fig. 2J) . Coinjection of CuCl 2 and APP His147→Ala/His149→Ala induced a lower astrocytic response around the injection site ( Fig. 3F and G) , indicating that this peptide is able to decrease this reaction and to diminish the hypertrophic astrocytes induced by CuCl 2 injection in all the evaluated conditions. It was also observed in a digital quantification of reactive astrocytes density (Fig. 3J) , intensity of GFAP staining in the soma (Fig. 3K) , and the size of the reative astrocyte soma (Fig. 3L) . On the other hand, rats co-injected with CuCl 2 and APP Cys144→Ser present higher escape latency values in the memory task close to the values observed by the rats injected with CuCl 2 alone. The absence of protection by APP Cys144→Ser against Cu 2+ neurotoxicity was independent of the pre-incubation protocol used ( Fig. 4C and D) , which was corroborated by quantification of neuronal cell density by Nissl staining (Fig. 2H, I, and J) . Moreover, immunodetection of GFAP showed a strong astrogliosis and hypertrophic astrocytes around the injection site, in all the conditions evaluated ( Fig. 3H and I) . It was also observed in a quantification of the reactive astrocytes (Fig. 3J-L) . These results suggest that Cu-reduction by the CuBD of APP is involved in the neuroprotective effects observed. (Fig. 5O-R) , at the level of the neuronal cell loss (Fig. 5M) and astrogliosis (Fig. 5N) .
Specific neuroprotective effects of APP
The dose response data was carried out, and the protection effect with APP 135-156 is in fact depending of the concentration of APP incubated with copper (Supplement data)
The CuBD of C. elegans APL-1 protects spatial memory against Cu 2+ neurotoxicity
To determine whether an APP homologue with variations within the central histidine binding site, but keeping the adjacent cysteine intact can protect against Cu 2+ toxicity, we used the C. elegans CuBD (APP 135-156 C. elegans ). This peptide was metallated by incubation with CuCl 2 and then dialyzed against aCSF to remove unbound Cu 2+ /Cu + or mixed with CuCl 2 and immediately injected. Rats co-injected with CuCl 2 and APP 135-156 C. elegans showed an escape latency score similar to control rats, which was independent to the incubation protocol used ( Fig. 6A; Fig. 6K shows a representative swimming paths for each treatment at day 8 of training). To analyze another sensitive spatial memory parameter, we calculated the "spatial acuity." This parameter was obtained after multiplication the percentage of animals present in the quadrant corresponding to the hidden platform (sec) by the percentage of animals present into the platform annulus (sec) (24, 25). Then, we calculated the mean of 10 trials of the water maze acquisition and plotted the escape latency vs. spatial acuity. Figure 6B shows that animals co-injected with CuCl 2 and APP 135-156 C. elegans in the two conditions of incubation are closer to the negative control animals (aCSF injection) than to the positive control (CuCl 2 ). Nissl staining of brain sections of rats co-injected with CuCl 2 and APP 135-156 C .elegans showed partial neuroprotection against Cu 2+ neurotoxicity ( Fig. 6C and D) in comparison with CuCl 2 alone (see Fig. 2B ); it was also observed in the quantification of neuronal cell density in the different conditions (Fig. 6E) . The immunodetection of GFAP showed a lower astrogliosis and a decrease of hypertrophic astrocytes induced by CuCl 2 around the injection site in the two treatments carried out ( Fig. 6F and G), in comparison with the animals injected with CuCl 2 alone (see Fig. 3B ). Moreover, a digital analysis of the reactive astrocytes was in agreement with the GFAP immunohistochemistry ( Fig. 6H-J) . These results suggest that the CuBD of the C. elegans APP and the CuBD of human APP shares neuroprotective activities against Cu 2+ neurotoxicity, despite their primary structure differences, suggesting a conserved function for this APP fragment through out evolution.
CuBD of APP prevents protein tyrosine nitration induced by CuCl 2
To determine whether the neuroprotective effect of APP against CuCl 2 neurotoxicity is mediated by an antioxidant pathway, we performed a nitrotyrosine immunodetection as an oxidative marker in the injection site of the animals, because it is well known that protein tyrosine nitration is an important marker of oxidative stress (26) . The anti-nitrotyrosine staining was carried out 1 wk after the intrahippocampal injection. Results indicate that the injection of aCSF did not show any positive signal (Fig. 7A) . On the other hand, CuCl 2 injection induced a clear signal for protein tyrosine nitration (Fig. 7B ). In agreement with our previous results, the co-injection of CuCl 2 and APP 135-156 present low levels of detection of nitrotyrosine signal (Fig. 7C) . When the APP Cys144→Ser was co-injected with CuCl 2 the protein nitration signal was increased (Fig. 7D) . Both, CuCl 2 plus APP His147→Ala/His149→Ala and CuCl 2 plus the APP fragment of C. elegans injections, present low levels of nitrotyrosine protein detection (Fig. 7E and F, respectively) . These data show that the formation of nitrotyrosine proteins is a downstream effect of the Cu 2+ neurotoxicity, which is abolished by the presence of the CuBD of APP, through a mechanism that involves Cu 2+ /Cu 1+ reduction.
CuBD of APP increases Cu 2+ uptake
To determine if differences in protection against Cu 2+ neurotoxicity by the CuBD peptides may be related to differences in Cu 2+ uptake, we co-injected 50 µM 64 CuSO 4 and 50 µM of the different CuBD peptides of APP (APP 135-156 , APP His147→Ala/His149→Ala , APP Cys144→Ser and APP 135-156 C.elegans ) and 14 h after the injection, Cu 2+ uptake was determined. Results show a 10-fold increase in the Cu 2+ uptake in the presence of human APP 135-156 (Fig. 8A ). In contrast, APP Cys144→Ser exhibited only a half effect of its wild-type counterpart in the Cu 2+ uptake (Fig.  8B ). Both APP His147→Ala/His149→Ala and APP 135-156 C.elegans induced an enhancement in Cu 2+ uptake (Fig. 8B) . These data are consistent with the idea that APP protects against Cu 2+ neurotoxicity by inhibiting the formation of reactive oxygen species by a direct modulation of the Cu 2+ levels at the extracellular space.
DISCUSSION
The physiological function of APP is unknown. However growing evidence support the idea that APP may be involved in the Cu homeostasis (27) . APP coordinates Cu forming bioinorganic complexes with high K d values (23) , suggesting a possible in vivo relevance (17) . APP contains in its structure clusters of amino acids ordinarily involved in Cu binding coordination such as histidines and cysteine. Moreover, some studies indicated that APP-deficient mice have elevated Cu levels in the liver and in cerebral cortex when compared with wild-type mice (15) . In addition, CuBD of APP are capable to reduce Cu 2+ to Cu 1+ (3, 4, 14) .
In this study, we evaluated whether the CuBD of APP modulates Cu 2+ neurotoxicity at the level of the hippocampus, performing intra-hippocampal injections in rats as an in vivo model. CuCl 2 was injected alone or co-injected with several synthetic peptides corresponding to the CuBD of human wild-type APP, human mutant APP peptides and APP ortholog of C. elegans. In addition, we carried out different treatments during the incubation of CuCl 2 with the peptides, injected immediately or preincubated overnight at 4°C or at 37°C. Due to the fact that results may be explained by the need to metallate Cu to the CuBD of APP to mediate its effect, as described by White et al. (16) , the different peptides used in this work were metallated. The Cu 2+ neurotoxic effect was analyzed by the neuropathological changes observed at the injection site as well as the spatial learning acquisition using the Morris water maze task.
In all experiments, we did not find any differences between the peptides metallated or not. Moreover, we did not find any evidence that Cu-metallated CuBD of APP induces neuronal cell death in vivo, as has been recently claimed by experiments in vitro (16).
Our studies indicated that when human APP 135-156 was injected plus CuCl 2 it clearly protected against the Cu 2+ toxicity at both the behavioral and histological levels, showing lower escape latency scores, neuronal cell loss, and astrogliosis. To evaluate the role of Cu binding vs. the Cureduction ability on the CuBD of APP neuroprotective properties, we used CuBD of APP mutated in histidines or cysteine residues (APP His147→Ala/His149→Ala and APP Cys144→Ser ). The coinjection of CuCl 2 plus APP His147→Ala/His149→Ala showed a similar protection to that observed with the APP 135-156 peptide. However, when CuCl 2 was co-injected with APP Cys144→Ser , the same neuroprotective effect was not observed; in fact higher escape latency values in the spatial memory test, increased hippocampal neuronal cell loss, and astrogliosis was found. Our studies indicate that the CuBD of APP protects against the Cu 2+ neurotoxicity because of its Cu 2+ /Cu 1+ reducing capacity. Interestingly, the same dependence on the reducing activity has been observed recently (28) . In that paper, it was used the CuBD of prion protein, which is able to bind and reduce copper. When CuCl 2 was injected in presence of the prion peptide lacking Trp residues (responsible to reduce copper), it was observed a decrease in the neuroprotective effect; however, the neuroprotection was observed with the prion peptide lacking His residues.
The specific effect observed by the injection of various divalent metals do not showed differences between the administration of the metal alone or with the metal plus APP 135-156 . CuCl 2 shows more neurotoxicity than ZnCl 2 ; however, in both cases, no recovery was observed with the APP 135-156 injection. The fragment used in this study may binds other divalent metals (18); however, the APP reducing activity was specific for copper. Therefore, APP 135-156 only shows protective effects on rat injected with CuCl 2 .
We also evaluate the effect of a homologue of the CuBD of human APP, the C. elegans ortholog APP 135-156 C. elegans . This CuBD peptide present variations within the central histidine binding domain, it binds Cu 2+ and maintains the adjacent cysteine (18) . The C. elegans peptide was coinjected with CuCl 2 , and a neuroprotective effect was found at both the behavioral and morphological levels. These results are consistent with a previous report showing that this peptide was also neuroprotective in vitro (16) .
An important point in the present work was to evaluate whether the copper-induced neurotoxicity was related to oxidative stress; specifically, it was of interest to study the presence of 3-nitrotyrosine residues, since these markers have been found in some neurodegenerative disorders. For example, in Parkinson disease (PD), it has been demonstrated that tyrosine hydroxylase, the enzyme responsible to synthetize dopamine, is a selective target for nitration after exposure to peroxinitrite, which induces the loss of the enzymatic activity (29) . Likewise, α-synuclein is also a selective target for tyrosine nitration, which may be relevant to the putative role of α-synuclein in the neurodegeneration observed in PD (30) . In the cerebrospinal fluid of Alzheimer's disease patients an increased concentration of 3-nitrotyrosine was found, concomitantly with decreasing cognitive functions. This suggests that activation of tyrosine nitration may play a role in the pathogenesis of Alzheimer's disease (31) . In transgenic mice expressing the human familial amyotrophic lateral sclerosis-linked SOD1 mutation (a mouse model for ALS), increased nitrotyrosine levels were found, suggesting that tyrosine nitration is one in vivo aberrant property of this ALS-linked SOD1 mutant (32) . In addition, hippocampal neurons showed an increased nitrotyrosine immunoreactivity after the exposure to FeSO 4 and Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (33) . Thus, it was of interest to study the presence of this oxidative stress marker, which is induced by peroxinitrite and catalyzed by transition metals like Cu 2+ (26) , and analyze if tyrosine nitration was occurring in the rat hippocampus after injection of CuCl 2 and if it was related to the magnitude of the hippocampal damage. We observed that the injection of CuCl 2 alone or CuCl 2 plus APP Cys144→Ser induced an important immunohistochemical nitrotyrosine signal, indicating that reactive oxidative species were generated inducing oxidative stress. In contrast, the co-injection of the human wild-type APP and the APP variant peptide without histidines plus CuCl 2 only showed a weak signal.
The protection observed with APP 135-156 is in agreement with previous studies demonstrating neuroprotective and neurotrophic activities for soluble APP (8) (9) (10) (11) (12) (13) . However, such results are not in apparent agreement with previous studies that showed that the CuBD of APP in vitro (16) or in neuronal cell cultures obtained from APP knockout mice present toxic effects (34) . One possible explanation for these differences may be related to the cellular Cu 2+ uptake; in fact, in the latter studies the authors did not find differences in the Cu 2+ uptake between wild-type and deficient-APP neurons; therefore, a possible increment in Cu 1+ concentration may induce toxic events, including lipid peroxidation. In contrast, in the present work we found an increased Cu 2+ uptake in the presence of the CuBD of APP peptides, which may be instrumental in decrease the extracellular Cu 1+ concentration, which in turn decreases Cu-dependent oxidative stress. For example, APP Cys144→Ser , which did not protect against Cu 2+ toxicity, presents a lower Cu-uptake capacity (50% less) than the wild-type APP , suggesting that the neuroprotection observed during the co-injection of the CuBD of APP plus CuCl 2 reflects not only a chelating property of the peptide. In fact, this is in aggrement with the idea that the intracellular milieu exhibits an overcapacity for Cu-chelation (35) and thus an increase incorporation of Cu may limit the toxicity of the metal in the extracellular milieu. Consistent with this idea, we observed an increment in the Cu 2+ uptake in the presence of APP peptides that present protection of both spatial memory capacities and hippocampal damage. + is a toxic ion, and both excess and deficiency lead to disorders such as Wilson's and Menkes's diseases (36) . In eukaryotic cells, the incorporation of Cu 2+ occurs in a reduced state, via the Cu 1+ -transporter hCtr1 (37, 38) . Therefore, the Cu-reducing activity of APP might serve in a favorable physiological function as a cell membrane Cu 2+ -reductase similar to Fre1 in yeast (39) , modulating the amount of Cu 1+ for subsequent uptake by Cu-transport proteins. In unfavorable conditions, an increase of APP on the cell surface may increase the reduction of Cu 2+ to Cu
1+
, generating an enhancement of Cu 1+ levels and free radicals and consequently causing an increased oxidative damage (4, 14, 40) .
In conclusion, our data indicate that the CuBD of APP can modulate Cu 2+ /Cu + availability in vivo, supporting the notion that the APP is involved in Cu 2+ /Cu + homeostasis (4, 17, 41, 42) . . After 14 h, radioactivity associated to hippocampus region was determined in a γ-counter as described in Materials and Methods. *P < 0.05.
